STERIS plc
NYSE:STE

Watchlist Manager
STERIS plc Logo
STERIS plc
NYSE:STE
Watchlist
Price: 216.06 USD -0.03% Market Closed
Market Cap: 21.3B USD
Have any thoughts about
STERIS plc?
Write Note

STERIS plc
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

STERIS plc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
STERIS plc
NYSE:STE
Stock-Based Compensation
$56.5m
CAGR 3-Years
4%
CAGR 5-Years
18%
CAGR 10-Years
16%
Medtronic PLC
NYSE:MDT
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Trinity Biotech PLC
NASDAQ:TRIB
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

STERIS plc
Glance View

Market Cap
21.3B USD
Industry
Health Care

STERRIS plc is a globally recognized leader in the field of infection prevention, surgical, and critical care solutions, committed to enhancing patient safety and healthcare efficiency. With a rich history spanning over 100 years, the company operates in more than 60 countries, offering a diverse range of products and services tailored to meet the needs of healthcare providers. STERIS’s innovative technologies, including sterilization and disinfection equipment, surgical tables, and integrated surgical suites, position it as a vital partner for hospitals and medical facilities striving to uphold high standards of patient care. This focus on innovation not only drives customer loyalty but also positions the company favorably in an industry that increasingly prioritizes safety and efficiency. For investors, STERIS presents a robust growth trajectory, bolstered by a strategic approach to acquisitions and an expansion into emerging markets. The company has consistently delivered strong financial results, reflecting resilience even amidst industry challenges. With an ongoing commitment to research and development, STERIS is well-positioned to leverage trends in healthcare modernization and increasing demand for infection control solutions. As global healthcare systems adapt to rising patient care standards and regulatory requirements, STERIS’s established reputation and forward-thinking strategies make it an attractive investment opportunity for those looking to capitalize on the evolving landscape of healthcare services.

STE Intrinsic Value
225.24 USD
Undervaluation 4%
Intrinsic Value
Price

See Also

What is STERIS plc's Stock-Based Compensation?
Stock-Based Compensation
56.5m USD

Based on the financial report for Sep 30, 2024, STERIS plc's Stock-Based Compensation amounts to 56.5m USD.

What is STERIS plc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
16%

Over the last year, the Stock-Based Compensation growth was 11%. The average annual Stock-Based Compensation growth rates for STERIS plc have been 4% over the past three years , 18% over the past five years , and 16% over the past ten years .

Back to Top